Ipamorelin
Selective GH secretagogue studied for ghrelin receptor signaling.
Evidence Level
Low
Research Type
/ System Mapping
Where this compound appears in research pathways
Research-only note: This mapping is educational and does not represent a treatment protocol.
/ 01
Overview
Selective GH secretagogue studied for ghrelin receptor signaling.
/ 02
Mechanism of Action
Studied for selective GHS-R activation with limited cortisol/prolactin effect.
/ 03
Research Applications
GH pulse research without broader hormonal disruption.
Studied for, research explores, preclinical models suggest, clinical studies have investigated.
/ 04
Studied Research Contexts
/ 05
Studied Research Dosing Ranges
Limited public data on dosing ranges across research models.
/ 06
Potential Adverse Effects Reported in Research
Adverse effect data is limited. Many compounds in this database lack human safety profiles.
/ 07
Mechanism Deep Dive
Ipamorelin is a selective growth hormone secretagogue. Research describes ghrelin receptor (GHS-R) activation that triggers GH release with reported selectivity relative to other pituitary hormones in some studies.
/ 08
Pathway Role
Sits within the ghrelin/GH-axis signaling pathway, parallel to GHRH-driven pathways.
/ 09
Biological Targets
/ 10
Research Applications
- Acute GH-release research
- Ghrelin receptor pharmacology studies
/ 11
Evidence Summary
Acute GH-release evidence exists. Limited clinical outcome evidence for downstream functional endpoints.
Evidence Level Rationale
Rated low due to limited clinical outcome trials measuring functional endpoints.
/ 12
Research Observation Timeline
Early Signal Window
Acute GH release within minutes to hours
Primary Study Window
Acute studies; limited long-term outcome data
Endpoint Type
Hormonal biomarker endpoints
Evidence Strength
Low (acute hormonal only)
/ 13
Safety & Unknowns
Long-term safety and outcome data for general use are not established.
/ 14
Research Limitations
Body composition or recovery outcome timing is not established in controlled human studies.
/ 15
References
References are being curated from peer-reviewed literature.
/ 07
Evidence Score
Overall Research Confidence
Low
Reflects breadth of mechanism, study type, and reproducibility across research literature.
/ 08
Related Peptides
CJC-1295
Long-acting GHRH analog studied in GH signaling research.
SS-31
Elamipretide
Mitochondrially-targeted tetrapeptide studied for cardiolipin interaction.
MOTS-c
Mitochondrial-derived peptide studied in AMPK signaling research.
Appears in pathways
For research and educational purposes only.
Not medical advice. Not intended to diagnose, treat, cure, or prevent disease. Compounds discussed may not be approved for human use. Any dosing information shown describes ranges studied in research settings — never a recommendation.